Coagulation Cascade

From a torn vessel to a solid clot

When a blood vessel is breached, the body has milliseconds-to-minutes to stop losing blood without clotting the entire circulation solid. Hemostasis solves this in two coordinated phases. Primary hemostasis is the platelet plug: platelets adhere to exposed collagen via von Willebrand factor, activate, and aggregate into a soft, fragile mass. Secondary hemostasis is the coagulation cascade proper — the enzymatic reinforcement that weaves a tough fibrin mesh through and around that platelet plug, locking it in place so it can withstand arterial pressure. The cascade is what this page is about, but the two are inseparable: the cascade runs on the phospholipid surface that activated platelets provide, and thrombin made by the cascade is itself one of the most powerful platelet activators.

The cascade is a relay of clotting factors — mostly serine protease zymogens (inactive enzyme precursors) synthesized by the liver and circulating in plasma. Each activated factor, marked with a lowercase "a" (for example factor Xa), cleaves and activates the next, so a tiny initial stimulus is amplified into an explosive burst. A few molecules of tissue factor can ultimately generate enough thrombin to clot a wound, because each step multiplies the signal. This is why it is called a cascade rather than a simple switch.

The three pathways: extrinsic, intrinsic, common

The classical "Y-shaped" diagram divides coagulation into three arms that converge on factor X.

The extrinsic pathway is the spark. Damage exposes tissue factor (factor III), a membrane protein normally hidden in the subendothelium and the walls of cells outside the bloodstream. Tissue factor binds circulating factor VIIa, and the tissue factor-VIIa complex directly activates factor X to Xa within seconds. It is called "extrinsic" because the trigger — tissue factor — is not normally present in flowing blood; it comes from outside the vascular compartment. In the body, this is the dominant physiological initiator of clotting.

The intrinsic (contact) pathway uses only components already present in plasma. It begins when factor XII contacts a negatively charged surface (in the lab, glass or kaolin; in vivo, collagen, polyphosphates from platelets, and other anionic surfaces), activating to XIIa, which activates XI to XIa, which activates IX to IXa. Factor IXa then teams up with its cofactor factor VIIIa to form the "tenase" complex, which activates factor X. This arm is slower but provides crucial amplification, and clinically it is the engine that hemophilia disables.

The common pathway begins at factor Xa, where both arms meet. Factor Xa combines with cofactor factor Va, calcium, and a phospholipid membrane to form the prothrombinase complex, which converts prothrombin (factor II) to thrombin. Assembling these enzymes on a surface, rather than letting them float freely, accelerates the reaction roughly a hundred-thousand-fold — geometry, not just chemistry, drives the cascade. Thrombin then cleaves fibrinogen (factor I) into fibrin and activates factor XIII, the transglutaminase that covalently cross-links fibrin strands into a mesh that resists mechanical and enzymatic breakdown.

Thrombin: the keystone and the brake

Thrombin is the climax of the cascade, and almost everything it touches accelerates clotting. Beyond cleaving fibrinogen, thrombin activates factors V, VIII, and XI — the very cofactors and enzymes upstream of its own production. This positive feedback is why thrombin generation is not gradual but explosive: an initial trickle from the tissue-factor pathway primes the system, then a self-amplifying burst produces the bulk of thrombin. The modern cell-based model of coagulation reframes the old cascade into three overlapping phases on cell surfaces: initiation on tissue-factor-bearing cells, amplification as the first thrombin primes platelets and activates cofactors, and propagation as the full thrombin burst occurs on the activated platelet surface.

Crucially, the same molecule is also a brake. When thrombin diffuses to intact endothelium and binds thrombomodulin, its substrate specificity flips: instead of clotting, it activates protein C, which with cofactor protein S degrades factors Va and VIIIa, shutting the cascade down at the edges of the wound. Together with antithrombin (which neutralizes thrombin and factor Xa, and is the target of heparin) and tissue factor pathway inhibitor, these systems confine the clot to the injury. Lose this restraint and clotting spreads — the genetic factor V Leiden mutation, which makes factor Va resistant to protein C, is the most common inherited cause of venous thrombosis in people of European descent.

The numbers that matter clinically

Coagulation is one of the most heavily lab-monitored systems in medicine because the consequences of getting it wrong — a stroke from too little clotting control, or a fatal bleed from too much anticoagulation — are immediate. The two workhorse tests interrogate different arms of the cascade.

The prothrombin time (PT), normally about 11-13 seconds, adds tissue factor to plasma and times the clot; it probes the extrinsic and common pathways (factors VII, X, V, II, and fibrinogen). Because reagents vary between labs, the PT is reported as the INR (International Normalized Ratio), standardized so that a patient not on anticoagulants sits near 1.0 and a typical warfarin target is 2.0-3.0. The activated partial thromboplastin time (aPTT), normally about 25-35 seconds, probes the intrinsic and common pathways and is used to monitor unfractionated heparin. Fibrinogen runs 200-400 mg/dL, and D-dimer — a fibrin breakdown fragment — is normally low but rises sharply with active clot turnover, making it a screening test for venous thromboembolism and a marker of DIC.

Two arms, two tests, two diseases

Feature	Extrinsic + common (PT / INR)	Intrinsic + common (aPTT)
Trigger in the assay	Tissue factor (thromboplastin)	Contact activator (kaolin, silica)
Factors tested	VII, X, V, II, fibrinogen	XII, XI, IX, VIII, X, V, II, fibrinogen
Normal range	~11-13 s (INR ~1.0)	~25-35 s
Drug it monitors	Warfarin (target INR 2.0-3.0)	Unfractionated heparin
Prolonged in isolation by	Factor VII deficiency, early warfarin, liver disease	Hemophilia A/B, factor XI deficiency, heparin, lupus anticoagulant

A useful clinical heuristic falls straight out of this table. If only the PT is prolonged, suspect factor VII (the shortest-lived vitamin K-dependent factor, so the first hit by warfarin or liver dysfunction). If only the aPTT is prolonged, suspect a hemophilia or contact-factor problem. If both are prolonged, the defect is in the common pathway, in fibrinogen, or in something that hits everything — severe liver disease, DIC, or a high dose of an anticoagulant.

Clinical correlations: when the cascade fails or runs away

• Hemophilia A and B. X-linked deficiencies of factor VIII and factor IX. Both prolong the aPTT with a normal PT and cause deep bleeding into joints and muscle. Severity tracks residual factor activity: under 1% causes spontaneous bleeds.
• Von Willebrand disease. The most common inherited bleeding disorder. Von Willebrand factor both anchors platelets and carries factor VIII; its loss impairs primary hemostasis and lowers factor VIII, blurring the line between platelet and cascade disease.
• Liver disease. The liver makes nearly every clotting factor, so cirrhosis prolongs the PT and aPTT. But it also makes the anticoagulants, leaving a precarious "rebalanced" hemostasis that can tip either way.
• Vitamin K deficiency. Without vitamin K, factors II, VII, IX, and X cannot be gamma-carboxylated and are functionally inert — the mechanism warfarin exploits, and the reason newborns receive a vitamin K injection.
• Disseminated intravascular coagulation (DIC). Systemic activation of the cascade by sepsis, trauma, or obstetric emergency consumes platelets and factors, producing simultaneous microthrombi and bleeding, with low fibrinogen and high D-dimer.
• Thrombosis. Too much clotting — factor V Leiden, prothrombin G20210A, antithrombin or protein C/S deficiency — predisposes to deep vein thrombosis and pulmonary embolism.

Drugs that tune the cascade

Because the cascade is a relay, it can be interrupted at almost any node, and modern pharmacology targets several. Warfarin blocks vitamin K epoxide reductase, starving factors II, VII, IX, and X of their post-translational activation; it acts over days and is monitored by INR. Heparin supercharges antithrombin to inactivate thrombin and factor Xa instantly; unfractionated heparin is monitored by aPTT, while low-molecular-weight heparins act mainly on Xa. Direct oral anticoagulants are more surgical: rivaroxaban and apixaban directly block factor Xa, and dabigatran directly blocks thrombin, generally without routine monitoring. On the bleeding-disorder side, factor concentrates replace what is missing, emicizumab mimics factor VIIIa to bridge factors IXa and X in hemophilia A, and gene therapy now offers durable factor expression. Separately, the fibrinolytic system — plasmin, generated from plasminogen by tissue plasminogen activator — dissolves clots once they are no longer needed, and clot-busting drugs in stroke and heart attack are recombinant tPA.

This article is educational and is not medical advice. Anticoagulation and bleeding disorders are managed by clinicians using individual lab values and history; do not start, stop, or adjust any medication based on this page.